Advertisement


Howard M. Sandler, MD, on Prostate Cancer: Prospective Trials Update

2018 ASTRO Annual Meeting

Advertisement

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses a session on data from several long-term studies on localized disease, including optimal sequencing of radiation and androgen-deprivation therapy; the efficacy and toxicity of SBRT; conventional vs hypofractionated radiation therapy; and dose escalation (Scientific Symposium 08).



Related Videos

Solid Tumors

David Palma, MD, PhD, on Oligometastatic Tumors: Results From the SABR-COMET Trial

David Palma, MD, PhD, of the London Health Sciences Centre, discusses study findings on improvement in survival following stereotactic ablative radiation for oligometastatic tumors...

Head and Neck Cancer

Bhisham Chera, MD, on Oropharyngeal Cancer: Expert Perspective on Surveillance

Bhisham Chera, MD, of the University of North Carolina, discusses using human papillomavirus found in plasma circulating tumor DNA to monitor cancer recurrence in HPV-associa...

Head and Neck Cancer
Symptom Management

Thomas Galloway, MD, on Oropharyngeal Cancer: Improving Outcomes and Reducing Toxicity

Thomas Galloway, MD, of Fox Chase Cancer Center, summarizes a session on head and neck cancer that included findings on reducing oral mucositis, improving quality of life with dein...

Issues in Oncology

Michael Soike, MD, on Brain Metastases: Radiosurgery vs Radiotherapy

Michael Soike, MD, of Wake Forest University Medical Center, discusses results from a large multicenter study that suggests salvage stereotactic radiosurgery leads to improved overall survival comp...

Lung Cancer
Immunotherapy

David Raben, MD, on NSCLC: Results From the PACIFIC Trial

David Raben, MD, of the University of Colorado, discusses overall survival with durvalumab vs placebo after chemoradiotherapy in stage III non–small cell lung cancer (Abstract LBA1...

Advertisement

Advertisement



;
Advertisement